A Comprehensive Systematic Review of The Effect of Topical Corticosteroid and Vitamin D Analog Combination Therapy on Psoriasis Remission Duration
Keywords:
Psoriasis, Topical Therapy, Combination Therapy, Corticosteroids, Vitamin D Analogs, Remission Duration, Calcipotriol, Betamethasone Dipropionate, Proactive Management, Systematic ReviewAbstract
Introduction: Topical therapy remains a cornerstone for mild-to-moderate psoriasis, but relapse after treatment cessation is a major challenge. The combination of topical corticosteroids (TCS) and vitamin D analogs (VDAs) has demonstrated superior efficacy over monotherapies for active treatment, yet comprehensive evidence on its long-term impact on remission duration is needed.
Methods: A systematic review was conducted based on a structured screening of literature from databases, adhering to predefined criteria. Studies involving adult patients with cutaneous psoriasis, evaluating concurrent topical TCS/VDA combination therapy, reporting remission duration or relapse data with ≥4 weeks follow-up, and employing controlled designs were included. Data on treatment regimens, remission definitions, relapse times, safety, and patient characteristics were extracted from 40 eligible sources.
Results: Proactive, long-term management with co-formulated calcipotriol/betamethasone dipropionate (Cal/BD) foam was the most effective strategy. The pivotal PSO-LONG trial demonstrated that twice-weekly proactive application nearly doubled the median time to first relapse (56 vs. 30 days) compared to reactive management, resulting in 41 additional days in remission per year (Lebwohl et al., 2020). Similar benefits were observed for other combinations, such as halobetasol/tazarotene lotion, which maintained treatment success in 38.2% of patients 4 weeks post-cessation versus 21.0% with halobetasol alone (Pariser et al., 2018). Systematic reviews confirmed the combination's superiority over VDA monotherapy (RR 2.28 for clearance) and a modest but significant benefit over potent corticosteroid monotherapy (RR 1.22) (Samarasekera et al., 2013; Queirós et al., 2017). The therapy was well-tolerated long-term, with no significant safety concerns over 52 weeks.
Discussion: The combination's efficacy stems from complementary anti-inflammatory, immunosuppressive, and keratinocyte-normalizing effects. The proactive regimen's success highlights the importance of treating subclinical inflammation to prevent relapse. Heterogeneity in outcomes is explained by differences in protocols (proactive vs. reactive), formulations (foam superiority), baseline disease severity, and combination types (co-formulated vs. sequential). The therapy offers a favorable risk-benefit profile, reducing overall corticosteroid exposure through sustained remission.
Conclusion: Proactive, long-term maintenance therapy with topical corticosteroid and vitamin D analog combinations, particularly Cal/BD foam, significantly prolongs psoriasis remission, reduces relapse frequency, and is a safe and effective first-line strategy for long-term disease control.
References
A. Bakulev, А. Л. Бакулев, D. Petrunin, and Д Д Петрунин. “Results of the Long-Term Observational Noninterventional Prospective Study BODYGUARD in Psoriasis Patients.” Vestnik Dermatologii i Venerologii, 2019.
A. Dattola, M. Silvestri, L. Bennardo, Maria Passante, F. Rizzuto, S. Dastoli, C. Patruno, L. Bianchi, and S. Nisticò. “A Novel Vehicle for the Treatment of Psoriasis.” Dermatologic Therapy, 2019.
A. Takhar, H. Thoning, B. Petersen, F. Salih, V. Kontogiannis, and N. Nyholm. “PSS10 Cost-Effectiveness of Proactive Management Versus Reactive Management with Calcipotriol/Betamethasone Dipropionate Foam for Treatment of Psoriasis Vulgaris in the UK,” 2020.
C. Queirós, G. Duarte, João Costa, and A. Vaz-Carneiro. “[Analysis of the Cochrane Review: Topical Treatments for Scalp Psoriasis. Cochrane Database Syst Rev. 2016;2:CD009687].” Acta Médica Portuguesa, 2017.
D. Pariser, L. Green, L. S. Stein Gold, J. Sugarman, Tina Lin, and R. Pillai. “Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.” Journal of Drugs in Dermatology, 2018.
E. Samarasekera, L. Sawyer, D. Wonderling, R. Tucker, and Catherine Smith. “Topical Therapies for the Treatment of Plaque Psoriasis: Systematic Review and Network Meta‐analyses.” British Journal of Dermatology, 2013.
G. Girolomoni, G. Vena, F. Ayala, S. Cannavò, O. De Pità, S. Chimenti, and A. Peserico. “Consensus on the Use of the Fixed Combination Calcipotriol/Betamethasone Dipropionate in the Treatment of Plaque Psoriasis.” Giornale Italiano Di Dermatologia e Venereologia : Organo Ufficiale, Societa Italiana Di Dermatologia e Sifilografia, 2012.
G. Vena, N. Cassano, C. Agnusdei, M. Bellini, S. Calabretta, S. Centofanti, G. Cervadoro, et al. “Treatment of Psoriasis Vulgaris with Calcipotriol Betamethasone Dipropionate Combination Followed by Calcipotriol and Assessment of the Adjuvant Basic Use of Urea-Based Emollients,” 2005.
Hao Chen, Jianfang Sun, Haizhen Yang, Qiuning Sun, Jianzhong Zhang, J. Gu, Hai Wen, et al. “Fixed Combination of Tazarotene and Betamethasone Dipropionate for Treatment of Psoriasis Vulgaris: The Result of a Phase 3, Multicenter, Randomized Controlled Trial.” Journal of Dermatology (Print), 2020.
J. G. Schlager, S. Rosumeck, R. Werner, A. Jacobs, J. Schmitt, C. Schlager, and A. Nast. “Topical Treatments for Scalp Psoriasis.” Cochrane Database of Systematic Reviews, 2016.
J. G. Schlager, S. Rosumeck, R. Werner, A. Jacobs, Jochen Schmitt, C. Schlager, and A. Nast. “Topical Treatments for Scalp Psoriasis: Summary of a Cochrane Systematic Review.” British Journal of Dermatology, 2017.
J. Koo, Robin R. Blum, and M. Lebwohl. “A Randomized, Multicenter Study of Calcipotriene Ointment and Clobetasol Propionate Foam in the Sequential Treatment of Localized Plaque-Type Psoriasis: Short- and Long-Term Outcomes.” Journal of American Academy of Dermatology, 2006.
J. Mason, A. Mason, and Michael J. Cork. “Topical Preparations for the Treatment of Psoriasis in Primary Care: A Systematic Review,” 2002.
J. Ortonne, R. Kaufmann, M. Lecha, and M. Goodfield. “Efficacy of Treatment with Calcipotriol/Betamethasone Dipropionate Followed by Calcipotriol Alone Compared with Tacalcitol for the Treatment of Psoriasis Vulgaris: A Randomised, Double-Blind Trial.” Dermatology, 2004.
Jacqueline Liu, Ahuva Cices, B. Kaufman, Ingrid Sanabria-Gonzalez, and A. Alexis. “Efficacy and Safety of Calcipotriene/Betamethasone Dipropionate Foam in the Treatment of Psoriasis in Skin of Color.” Journal of Drugs in Dermatology, 2023.
K. Kragballe, J. Austad, L. Barnes, A. Bibby, M. Brassinne, F. Cambazard, C. Fleming, et al. “Efficacy Results of a 52-Week, Randomised, Double-Blind, Safety Study of a Calcipotriol/Betamethasone Dipropionate Two-Compound Product (Daivobet®/Dovobet®/Taclonex®) in the Treatment of Psoriasis Vulgaris.” Dermatology, 2006.
K. Papp, Z. Adamski, L. Guenther, M. Liljedahl, Agnieszka Miasik-Pogodzinska, Anna Szponar-Bojda, C. Lynde, et al. “Efficacy and Safety of Proactive Treatment with Twice-Weekly Topical Cal/BD Foam in Patients with Plaque Psoriasis Undergoing HPA-Axis Testing: A PSO-LONG Subgroup Analysis.” Journal of Dermatological Treatment (Print), 2021.
L. Gold, J. Weiss, L. Green, L. Kircik, Tina Lin PharmD, and S. Harris. “15324 Long-Term Management of Moderate to Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Patients with Baseline Body Surface Area of 6%-12%,” 2020.
L. Gold, M. Lebwohl, N. Bhatia, Tina Lin, and R. Pillai. “605 Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion,” 2020.
L. Kircik, T. Schlesinger, and E. Tanghetti. “Efficacy and Safety of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam With Apremilast for Moderate Plaque Psoriasis.” Journal of Drugs in Dermatology, 2020.
L. S. Stein Gold, J. Alonso‐Llamazares, J. Lacour, R. Warren, S. Tyring, L. Kircik, P. Yamauchi, and M. Lebwohl. “PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in Psoriasis.” Advances in Therapy, 2020.
L. S. Stein Gold, J. Bagel, M. Lebwohl, Tina Lin, Gina Martin, and R. Pillai. “Halobetasol and Tazarotene: Further Defining the Role of a Unique Fixed Combination Topical Lotion in Moderate-to-Severe Plaque Psoriasis.” Journal of Drugs in Dermatology, 2018.
M. Lahfa, U. Mrowietz, Miriam Koenig, and J. Simon. “Calcitriol Ointment and Clobetasol Propionate Cream: A New Regimen for the Treatment of Plaque Psoriasis.” EJD. European Journal of Dermatology, 2003.
M. Lebwohl, J. Lacour, M. Liljedahl, C. Lynde, M. Mørch, Anja Snel-Prentø, D. Thaçi, and R. Warren. “12797 Safety of Long-Term Proactive Management with Fixed-Dose Combination Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam in Patients with Psoriasis Vulgaris: Results of a Phase III, Multicenter, Randomized, 52-Week, Vehicle-Controlled Trial,” 2020.
———. “18223 Long-Term Proactive Management of Psoriasis Vulgaris with Fixed-Dose Combination of 0.005% Calcipotriene and 0.064% Betamethasone Dipropionate Foam: Results of a Phase III Randomized Controlled Trial,” 2020.
M. Lebwohl, Jean Philippe LACOUR, M. Liljedahl, C. Lynde, M. Mørch, Anja Snel-Prentø, L.E.O. Pharma, D. Thaçi, and R. Warren. “16830 Results from the Open-Label Treatment Period of a Long-Term Proactive Management Phase III Trial Using Fixed-Dose Combination Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam,” 2020.
M. Lebwohl, K. Papp, M. Mørch, and J. Andersen. “32805 Analysis of Time to Second Relapse Confirms the Superiority of Long-Term Proactive Management with Cal/BD Foam Vs Reactive Management of Psoriasis.” Journal of American Academy of Dermatology, 2022.
M. Lebwohl, K. Papp, M. Mørch, Marie Y. Jablonski Bernasconi, and R. Warren. “Long-Term Proactive Treatment of Plaque Psoriasis with Calcipotriene/Betamethasone Dipropionate Foam Prolongs Remission and Reduces Relapses Irrespective of Patient Baseline Characteristics.” Dermatologic Therapy, 2021.
M. Lebwohl, L. Kircik, J. Lacour, M. Liljedahl, C. Lynde, M. Mørch, K. Papp, et al. “Twice-Weekly Topical Calcipotriene / Betamethasone Dipropionate Foam as Proactive Management of Plaque Psoriasis Increases Time in Remission and Is Well Tolerated over 52 Weeks (PSO-LONG Trial).” Journal of American Academy of Dermatology, 2020.
M. Sindhuja, and N. Muthiah. “Efficacy and Safety of Topical Calcipotriol Plus Betamethasone Dipropionate Versus Topical Betamethasone Dipropionate Alone in Mild to Moderate Psoriasis.” Journal of Pharmaceutical Research International, 2021.
Marjorie Heim, M. Irondelle, L. Duteil, N. Cardot-Leccia, S. Rocchi, T. Passeron, and M. Tulic. “Impact of Topical Emollient, Steroids Alone or Combined with Calcipotriol, on the Immune Infiltrate and Clinical Outcome in Psoriasis.” Experimental Dermatology, 2022.
N. Katoh, and S. Kishimoto. “Combination of Calcipotriol and Clobetasol Propionate as a Premixed Ointment for the Treatment of Psoriasis.” EJD. European Journal of Dermatology, 2003.
P. Gisondi, T. Gracia-Cazaña, Hjalmar Kurzen, and Jordi Galván. “Calcipotriol/Betamethasone Dipropionate for the Treatment of Psoriasis: Mechanism of Action and Evidence of Efficacy and Safety Versus Topical Corticosteroids.” Journal of Clinical Medicine, 2024.
P. Peeters, J. Ortonne, René Sitbon, and E. Guignard. “Cost-Effectiveness of Once-Daily Treatment with Calcipotriol/Betamethasone Dipropionate Followed by Calcipotriol Alone Compared with Tacalcitol in the Treatment of Psoriasis Vulgaris.” Dermatology, 2005.
R. Saraceno, L. Andreassi, F. Ayala, M. Bongiorno, A. Giannetti, P. Lisi, P. Martini, K. Peris, A. Peserico, and S. Chimenti. “Efficacy, Safety and Quality of Life of Calcipotriol/Betamethasone Dipropionate (Dovobet®) Versus Calcipotriol (Daivonex®) in the Treatment of Psoriasis Vulgaris: A Randomized, Multicentre, Clinical Trial.” Journal of Dermatological Treatment (Print), 2007.
R. Warren, M. Gold, M. Gooderham, L. Kircik, J. Lacour, P. Laws, M. Liljedahl, et al. “Four-Week Daily Calcipotriene/Betamethasone Dipropionate Foam Is Highly Efficacious in Patients With Psoriasis (PSO-LONG Lead-in Phase).” Journal of Drugs in Dermatology, 2021.
Ru Yan, Shi-Bin Jiang, Yan Wu, Xing-Hua Gao, and Hong-Duo Chen. “Topical Calcipotriol/Betamethasone Dipropionate for Psoriasis Vulgaris: A Systematic Review.” Indian Journal of Dermatology, Venereology and Leprology, 2016.
T. Luger, F. Cambazard, F. G. Larsen, M. Bourcier, G. Gupta, F. Clonier, P. Kidson, and N. Shear. “A Study of the Safety and Efficacy of Calcipotriol and Betamethasone Dipropionate Scalp Formulation in the Long-Term Management of Scalp Psoriasis.” Dermatology, 2008.
Yi Zhao, A. Asahina, P. Asawanonda, M. Frez, S. Imafuku, Dong Hyun Kim, C. Theng, Liang-Chou Wang, Jiang-an Zhang, and S. Zimmo. “Systematic Review and Practical Guidance on the Use of Topical Calcipotriol and Topical Calcipotriol with Betamethasone Dipropionate as Long‐term Therapy for Mild‐to‐moderate Plaque Psoriasis.” Journal of Dermatology (Print), 2021.
朱品华. “卡他西醇和卤米松联合nb-Uvb治疗寻常型银屑病 Tacalcitol and Sicorten Combined NB-UVB Treatment of Psoriasis Vulgaris,” 2015.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Dio Vaszdly Pramana Sukardi, Finda Rahmanisa (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors publishing here keep copyright but grant the journal first publication rights, under a Creative Commons Attribution-NonCommercial 4.0 License. They can distribute their work non-exclusively elsewhere with an acknowledgment of its first publication in this journal. Posting the work online before and during submission for earlier and greater citation is encouraged, reflecting Open Access benefits.
